Koivula, R. W., Forgie, I. M., Kurbasic, A., Viñuela, A., Heggie, A., Giordano, G. N., Hansen, T. H., Hudson, M., Koopman, A. D. M., Rutters, F., Siloaho, M., Allin, K. H., Brage, S., Brorsson, C. A., Dawed, A. Y., De Masi, F., Groves, C. J., Kokkola, T., Mahajan, A., ... IMI-DIRECT consortium (2019). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 62(9), 1601-1615. https://doi.org/10.1007/s00125-019-4906-1
Koivula, RW, Forgie, IM, Kurbasic, A, Viñuela, A, Heggie, A, Giordano, GN, Hansen, TH, Hudson, M, Koopman, ADM, Rutters, F, Siloaho, M, Allin, KH, Brage, S, Brorsson, CA, Dawed, AY, De Masi, F, Groves, CJ, Kokkola, T, Mahajan, A, Perry, MH, Rauh, SP, Ridderstråle, M, Teare, HJA, Thomas, EL, Tura, A, Vestergaard, H, White, T, Adamski, J, Bell, JD, Beulens, JW, Brunak, S, Dermitzakis, ET, Froguel, P, Frost, G, Gupta, R, Hansen, T, Hattersley, A, Jablonka, B, Kaye, J, Laakso, M, McDonald, TJ, Pedersen, O, Schwenk, JM, Pavo, I, Mari, A, McCarthy, MI, Ruetten, H, Walker, M, Pearson, E, Franks, PW & IMI-DIRECT consortium 2019, 'Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium', Diabetologia, bind 62, nr. 9, s. 1601-1615. https://doi.org/10.1007/s00125-019-4906-1
@article{9683c468dc334b5a86f00a7d21d9f8df,
title = "Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium",
abstract = "AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).METHODS: From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.RESULTS: Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.CONCLUSIONS/INTERPRETATION: The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.",
author = "Koivula, {Robert W} and Forgie, {Ian M} and Azra Kurbasic and Ana Vi{\~n}uela and Alison Heggie and Giordano, {Giuseppe N} and Hansen, {Tue H.} and Michelle Hudson and Koopman, {Anitra D M} and Femke Rutters and Maritta Siloaho and Allin, {Kristine H.} and S{\o}ren Brage and Brorsson, {Caroline A} and Dawed, {Adem Y} and {De Masi}, Federico and Groves, {Christopher J} and Tarja Kokkola and Anubha Mahajan and Perry, {Mandy H} and Rauh, {Simone P} and Martin Ridderstr{\aa}le and Teare, {Harriet J A} and Thomas, {E Louise} and Andrea Tura and Henrik Vestergaard and Tom White and Jerzy Adamski and Bell, {Jimmy D} and Beulens, {Joline W} and S{\o}ren Brunak and Dermitzakis, {Emmanouil T} and Philippe Froguel and Gary Frost and Ramneek Gupta and Torben Hansen and Andrew Hattersley and Bernd Jablonka and Jane Kaye and Markku Laakso and McDonald, {Timothy J} and Oluf Pedersen and Schwenk, {Jochen M} and Imre Pavo and Andrea Mari and McCarthy, {Mark I} and Hartmut Ruetten and Mark Walker and Ewan Pearson and Franks, {Paul W} and {IMI-DIRECT consortium}",
year = "2019",
month = sep,
day = "1",
doi = "10.1007/s00125-019-4906-1",
language = "English",
volume = "62",
pages = "1601--1615",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "9",
}
TY - JOUR
T1 - Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes
T2 - descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium
AU - Koivula, Robert W
AU - Forgie, Ian M
AU - Kurbasic, Azra
AU - Viñuela, Ana
AU - Heggie, Alison
AU - Giordano, Giuseppe N
AU - Hansen, Tue H.
AU - Hudson, Michelle
AU - Koopman, Anitra D M
AU - Rutters, Femke
AU - Siloaho, Maritta
AU - Allin, Kristine H.
AU - Brage, Søren
AU - Brorsson, Caroline A
AU - Dawed, Adem Y
AU - De Masi, Federico
AU - Groves, Christopher J
AU - Kokkola, Tarja
AU - Mahajan, Anubha
AU - Perry, Mandy H
AU - Rauh, Simone P
AU - Ridderstråle, Martin
AU - Teare, Harriet J A
AU - Thomas, E Louise
AU - Tura, Andrea
AU - Vestergaard, Henrik
AU - White, Tom
AU - Adamski, Jerzy
AU - Bell, Jimmy D
AU - Beulens, Joline W
AU - Brunak, Søren
AU - Dermitzakis, Emmanouil T
AU - Froguel, Philippe
AU - Frost, Gary
AU - Gupta, Ramneek
AU - Hansen, Torben
AU - Hattersley, Andrew
AU - Jablonka, Bernd
AU - Kaye, Jane
AU - Laakso, Markku
AU - McDonald, Timothy J
AU - Pedersen, Oluf
AU - Schwenk, Jochen M
AU - Pavo, Imre
AU - Mari, Andrea
AU - McCarthy, Mark I
AU - Ruetten, Hartmut
AU - Walker, Mark
AU - Pearson, Ewan
AU - Franks, Paul W
AU - IMI-DIRECT consortium
PY - 2019/9/1
Y1 - 2019/9/1
N2 - AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).METHODS: From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.RESULTS: Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.CONCLUSIONS/INTERPRETATION: The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.
AB - AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).METHODS: From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.RESULTS: Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.CONCLUSIONS/INTERPRETATION: The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.
U2 - 10.1007/s00125-019-4906-1
DO - 10.1007/s00125-019-4906-1
M3 - Journal article
C2 - 31203377
SN - 0012-186X
VL - 62
SP - 1601
EP - 1615
JO - Diabetologia
JF - Diabetologia
IS - 9
ER -
